1. 308 Tralokinumab provides other clinically meaningful improvements in adolescents with moderate-to-severe atopic dermatitis who did not achieve IGA 0/1 at week 16. (25th January 2023) Authors: Paller, Amy; Blauvelt, Andrew; Soong, Weily; Hong, Chih-ho; Schuttelaar, Marie L A; Schneider, Shannon ; Moerch, Marie Holst; Simpson, Eric Journal: British journal of dermatology Issue: Volume 188(2023)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗